Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the companies laid the case to rest with a settlement agreement. Novartis ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations , with sales up 19.5% year on year to $1.05 billion. Its non ...

WILMINGTON, Del. (AP) — WILMINGTON, Del. (AP) — Incyte Corp. (INCY) on Tuesday reported first-quarter profit of $158.2 million. The Wilmington, Delaware-based company said it had profit of 80 ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Incyte INCY in the last three months. The following table summarizes their recent ratings ...

Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago. These figures ...

April 29 (Reuters) - Incyte Corp (INCY.O), opens new tab raised the annual sales forecast for its blood cancer drug Jakafi on Tuesday, and said it expects minimal impact from U.S. tariffs due to ...

April 29, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today reports 2025 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.

The decrease in margin was driven by higher expenses. EPS: US$0.82. We've discovered 2 warning signs about Incyte. View them for free. Revenue exceeded analyst estimates by 5.5%. Earnings per ...

Incyte Corporation reported a strong start to 2025, posting first-quarter earnings that surpassed Wall Street’s expectations. The company recorded an earnings per share (EPS) of $1.16, exceeding ...

Michael Schmidt, Guggenheim ... were reassured by management’s confidence in Povorcitinib’s Phase 3 data. Incyte reported a strong start to 2025, driven by impressive growth in Jakafi and ...